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Available online 4 June 2016This article aims to put into perspective the binary opposition between ‘scientiﬁc’ clinical research trials and
‘rogue’ experimental stem cell therapies, and to showwhy the ethics criteria used by the dominant science com-
munity are not suitable for distinguishing between adequate and inadequate treatments. By focusing on the grey
area between clinical stem cell trials and stem cell experimentation, the experimental space where patients,
medical professionals and life scientists negotiate for diverging reasons and aims, I show why idealised notions
of ethics are not feasible for many stem cell scientists in low- and middle-income countries.
Drawing on ﬁeldwork in China from 2012 to 2013, the article asks why ‘the unethical’ according to some is ac-
ceptable to Chinese life scientists. The case study of stem cell service provider Beike Biotech illustrates how
stem cell interventions take place in a large grey area, where narrow notions of ethics are blurred with and
supplanted by broader notions of ethics, co-determined by estimations of socio-economic, political and cultural
understandings of risk, opportunity and beneﬁt.
I borrow the term ‘bionetworking’, understood as the entrepreneurial aspects of scientiﬁc networks that engage
in creating biomedical products, to analyse various forms ofmedical experimentation. I speak of the ‘externalisa-
tion’ and ‘internalisation’ of local factors to elucidate how features of patient populations and their environments
are subsumed in clinical research applications. Compared to polarised views of stem cell therapy, this approach
increases the transparency of clinical interventions and broadens our understanding of why ‘stem cell tourism’ to
some is ‘stem cell therapy’ to others.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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In the context of ‘stem cell tourism’, scientists and observers of ethics
have made sharp distinctions between randomised controlled trials
(RCTs) and ‘experimental’ stem cell therapy provision. Various forms
and practices of stem cell research and therapy have been criticised, re-
ported and analysed by social scientists and the press (e.g., McMahon
and Thorsteinsdóttir, 2010; The Economist, 2002; Sipp, 2011; Main
et al., 2014; Ogbogu et al. 2013; Cyranoski, 2012). Governments in the
US, Hungary, the Netherlands, Germany, Ireland, Belize and elsewhere
have closed down clinics that provide ‘unauthorised’ stem cell therapies,
while others fail to stop stem cell providers from charging high fees to ad-
minister ‘unproven therapies’ (Sipp 2009). The distinctions between ‘le-
gitimate’ and ‘illegitimate’, ‘evidence-based’ and ‘traditional’, andous reviewers of this article and
ical concerns, supporting data
eﬁted from ﬁnancial support
9) and the Economic and Social
This is an open access article under t‘science-based’ and ‘experimental stem cell therapies’ are subject to heat-
ed discussion among established scientists and critics. These distinctions
presume that clinical stem cell interventions that are ‘unproven’ are ap-
plied only by quacks (Bharadwaj, 2013): notwith the aim to cure disease,
but to exploit innocent victims.
Some works on the clinical application of stem cells in LMICs have
emphasised the importance of analysing regenerative medicine in the
context of globalisation, global politics and global governance
(Webster, 2013; Zhang, 2012; Bharadwaj, 2013; Chen and Gottweis,
2013; Sleeboom-Faulkner and Patra, 2011; Sleeboom-Faulkner, 2014).
These and others (Salter et al., 2015) have especially focused on the cen-
tral role of bioethics in the global hegemony of ‘Western’ stem cell sci-
ence, whereby bioethics and stem cell governance have become a
pawn in a global race. Rather thanmaking another claim about the glob-
al hegemony of ‘Western’ bioethics, I aim to identify how bioethics is
understood in the light of local conditions. I do this by contrasting the
local socio-economic, cultural and political factors that are important
in the appreciation of clinical stem cell applications, and by exploring
a way to relate the polarising and normative discussions of research
ethics mentioned above to local factors relevant to the bionetworks, ex-
plained in the section below.he CC BY license (http://creativecommons.org/licenses/by/4.0/).
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work for relations between institutions, and that raising ethical issues
in an institutional context can confuse the issues that cannot be
subsumed in terms of ethical guidelines (Coates, 1994). Thus, a narrow
focus on a narrow deﬁnition of ethics has made medical fees, medical
ethics and scientiﬁc research fraud central to thinking about ‘rogue’
experimental stem cell provision (Sipp 2009; McMahon and
Thorsteinsdóttir, 2010; Sipp, 2011; Main et al., 2014; Ogbogu et al.
2013; Cauldﬁeld, 2015). But generalising and preconceived notions of
global inequality, exploitation, and human experimentation on the
poor and desperate fail to take into account the variability of their insti-
tutional embedding: they are unable to capture the signiﬁcance of the
active roles of patients, scientists and governments that facilitate inno-
vative clinical stem cell applications in low- and middle-income coun-
tries (LMICs). The ethics of stem cell interventions, then, need to be
understood in the socio-economic context in which its gains meaning,
signiﬁcance and is implemented. Rather than doing away with ethics,
or understanding the ethics of stem cell applications in terms of
‘rogue’ and bona ﬁde’, this approach leads to a more realistic estimation
of the meaning of ‘international ethics' and the reasons for its lack of
implementation.
Accounts of local factors underlying such applications are needed to
nuance the binary that has been created between ‘good’ RCTs and
‘rogue’ stem cell experimentation (SCE) (see Table 1).
In practice, most forms of clinical stem cell research feature a combi-
nation of these ideal-typical features, enabled by the various experi-
mental spaces available in countries globally (Sleeboom-Faulkner
et al., 2016). By putting this binary into perspective this article tries to
move beyond the view that good clinical practice is a matter of
money, ethics and evidence-based science. Instead, it emphasises the
importance of local factors that structure the exchanges between pa-
tients and research enterprises in shaping the clinical stem cell inter-
ventions that take place. This shift of focus from a narrow approach to
ethics to value realisation through exchange networks in the life sci-
ences increases the number of factors relevant to the ethics underlying
the development and practice of clinical stem cell applications.
1.1. Bionetworking
In clinical stem cell research and its applications the value of scientif-
ic knowledge, medical skills, management andmaterials (including lab-
oratories, assays, serums andbiologics) are realised throughmany kinds
of knowledge and material exchanges. They are expressed in a range of
commercial and trading assets, including iPR, product licencing, accred-
itations and scientiﬁc collaborations, and materialised in the trade of
equipment and biomaterials, and clinical services. Value realisation
here (Birch and Tyﬁeld, 2012) requires the strategic deployment of a
range of socioeconomic relationships, entailing entrepreneurial skills,
planning and management (Jones et al., 2011). While the wellbeing of
the patient may be central to scientists' concerns, it is clear that there
are many other factors that condition their ability to sustain their
work successfully, be it in an academic department, a company or a clin-
ic. Central to value realisation in the life sciences is theway inwhich ex-
changes are positioned in strategic networks shaped through socio-
economic, political-legal and cultural factors, or, ‘bionetworking’Table 1
The binary between RCT and SCE.
RCT SCE
Reliability Bona ﬁde Rogue
Quality practice GMP, GLP, GCP Dubious
Ethics Informed consent, IRB Dishonest, no oversight
Quality results Scientiﬁc, evidence-based Unscientiﬁc
Beneﬁt For humanity Exploitative
Procedures Scientiﬁc protocol Experimental
Knowledge Generalizable Inadequate(Sleeboom-Faulkner and Patra, 2011), also involving a myriad of non-
scientiﬁc activities, including networking, lobbying, managing, trading,
and collaborating to produce science. These activities encompass inter-
actions with a wide variety of stakeholders and institutions, ranging
from political agencies, corporate sponsors and subsidiary companies
to patient groups, local hospitals, universities, and the media. Such
‘bionetworking’ activities, according to Sleeboom-Faulkner and Patra,
can be used to justify, prepare, and realise life science research and its
applications in marked localities, incentivised not just by the promise
of scientiﬁc results, but also by the demand of clients, collaborative part-
ners, funding providers and by the development of new knowledge as-
sets (Sleeboom-Faulkner and Patra, 2011). The value realisation in
bionetworks differs from the notion of biovalue, which pertains to the
yield of vitality produced by the biotechnical reformulation of living
processes (Waldby, 2002). Bionetworking refers to social entrepreneur-
ial network activities involving biomedical research and healthcare in-
stitutions that respond to health demands and needs (Patra and
Sleeboom-Faulkner 2009). A bionetwork consists of a plurality of actors
engaged in ‘biotechnical ventures’ (Waldby andMitchell 2007)working
across geographical spaces, regulatory regimes and social institutions.
Bionetworks relate to the entrepreneurial aspects of biomedicine, and
the strategic use of the differences and similarities in the provision of
healthcare, levels ofwealth, standards of scientiﬁc development, and re-
search regulatory regimes and their implementation (Sleeboom-
Faulkner and Patra, 2011). The notion applies to translational scientists
workingwith research budgets ﬁnanced by the state, as well as to those
working on a commercial basis.
1.2. The local shaping of clinical interventions
This article tries to shed light on the distinction between RCTs and
SCE in terms of bionetworking, taking into consideration what I refer
to as the internalisation and externalisation of local factors; it aims to
understand the merits of clinical stem cell interventions, rather than
projecting a narrowdeﬁnition of bioethics onto theﬁeld. Some scientiﬁc
approaches to clinical interventions, such as RCTs, emphasise the gener-
ation of scientiﬁc value rather than the value of immediate cures (Main
et al., 2014). A scientiﬁc approach would translate ‘local’ circumstances
interveningwith a clinical trial as external factors for the purpose of cre-
ating generalizable knowledge. It presumes that, only on the basis of
such generalizable knowledge, science can serve the creation of efﬁca-
cious therapy in the long run. This bracketing of local particularity exter-
nalises factors that deﬁne the patients and their environments as
potentially intervening with the aim of universal applicability of the
therapeutic product (Will andMoreira, 2010). Although RCTs are usual-
ly regarded as a case in point, clinical research methods of lesser pre-
tence also externalise local factors. For instance, the absence of
Western medical knowledge among ‘subjects’ at a medical research
site in, say Somalia, can be remedied - externalised - by providing re-
search participants with training and instructions regarding the kind
of hygiene required, or by temporarily housing research participants
in a clinic that conforms to the ideal environment for the experimental
research. It is also possible, on the other hand, to utilise the local factors
that deﬁne patients and their environments to facilitate the local appli-
cability of a therapeutic product: to internalise local factors. For in-
stance, researchers, including those linked with RCTs, might target
populations that are ‘medically naïve’, or populations that have a partic-
ular genetic or epidemiological proﬁle. Researchers are also interested
in populations with rare diseases, incurable diseases and populations
that have no alternative healthcare options. Members of all of these
populations can become targets for clinical interventions, and in all of
these cases the aims of the intervention may be multiple, and can, in
principle, include the acquisition of research results, proﬁt, biomaterials,
experience, and the expression of compassion and duty. Thus, depend-
ing on the context and arrangements made, the application of clinical
interventions are decided not only on the basis of disease conditions,
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jects, healthcare access, and the ability of patients to pay for treatment.
I aim to show that, if the internal logic of experimental clinical inter-
ventions cannot be explained in satisfactory terms of the in/externalisa-
tion of factors in the interest of the research and the patient
(population), it may well cover up controversial aims, including the
pursuit of proﬁt at the expense of patients. By avoiding narrow bioeth-
ical approaches,wemay be able to startmapping the large grey area be-
tween idealised scientiﬁc research and demonised stem cell tourism. A
focus on how local factors are dealt with in an international context
can help nuance the binary of RCTs and SCE (see Table 2), and enable
us to understand why ‘unethical’ stem cell applications are ‘acceptable’
to some.
Social-science writing critical of RCTs problematizes the ways phar-
maceutical companies and research institutions operate. One of the
most scathing points of critique has been that RCTs proceed from
idealised circumstances to further scientiﬁc knowledge, without sufﬁ-
ciently taking into account the local conditions in which trials take
place (e.g., Will and Moreira, 2010; Rajan, 2006; Petryna, 2009;
Mirowski and Sent, 2002; Fisher, 2009; Dumit 2012). By externalising
local variability, the medicine resulting from expensive RCTs may be-
come unsuitable for local use (Zwarenstein and Oxman, 2006;
Montgomery 2012), while its adherence to ‘universal regulation’ may
delay or change the direction of research.
But, in fact, some RCTs include local variability in the logic of clinical
trials, comparing the effectiveness of research over a number of locali-
ties, internalising relevant difference into the trial as variables. RCTs
do not just test safety and efﬁcacy, but increasingly aim to observe the
social functioning of treatments and set priorities for spending (Will
andMoreira, 2010). As such, clinical trials can result in clinical interven-
tions appropriate to ‘local daily life’ rather than the fabricated ‘ideal’
conditions of universal applicability. Such clinical trials tailor-made to
the circumstances of patients are also referred to as ‘pragmatic clinical
trials’ (Patsopoulos, 2011). The struggle to make RCTs more ‘relevant’
to real world problems and populations requires researchers to take
into account institutional settings and to accommodate variation
among the circumstances of patients (Will, 2007). The work by Steven
Epstein on the properties and designs of AIDS in the 1980s (Epstein,
1996) exempliﬁes how new approaches can accommodate the de-
mands and circumstances of patients to hasten results and distribute
potential beneﬁts. In the context of stem cell research, too, we observe
a trend of global patient mobility and local patient demands shaping
and facilitating internationally unaccepted forms of experimental stem
cell therapy provision (Chen and Gottweis, 2013; Salter et al., 2015).
In fact, over the last few years, new forms of regulation have devel-
oped that allow ‘early’ clinical interventions. For instance, in South
Korea and Japan, it is now possible to start conditional marketisation
of stem cell products that have only been through limited safety and ef-
ﬁcacy testing (KFDA, 2010;MFDS, 2013; PMDA, 2014), while in the USA
and EU, regulatory spaces have beenmade available for the early clinical
testing of ATMPs (US FDA, 2014a, 2014b, 2014c; EMA, 2014; MHRA,Table 2
The grey area and the binary
RCT Grey area SCE
Reliability Bona ﬁde This area is not a neat combination of
the merits of RCT and demerits of SCE,
as they form an illusive binary.
Instead, we need to examine the
ways in which local factors enable
research to take shape through
bionetworks.
Rogue
Quality GMP, GLP,
GCP
Unsure
Research
ethics
Informed
consent, IRB
Dishonest,
no oversight
Scientiﬁc
results
Generalizable Unscientiﬁc
Beneﬁt All humanity Exploitative
Procedures Scientiﬁc
protocol
Experimental
Knowledge Universal Inadequate2014). It is, however, stem cell interventions that are not subject to ef-
fective regulation that have been under heavy scrutiny, and an insis-
tence on the implementation of the standard ethics of idealised
clinical trials has incapacitated translational research in LMICs, such as
China and India (Rosemann and Sleeboom-Faulkner, 2016; Bharadwaj,
2013). Although discouraging regulatory provisions have been in place
in both countries (ICMR-DBT, 2012, 2013; Sui and Sleeboom-Faulkner,
2015), life scientists have created alternative ways of conducting re-
search and responding to patient demands at the same time.
Internalising local conditions with respect to regulation, expertise,
healthcare, patient demand, regulatory oversight, and laboratory re-
sources, researchers have set themselves various purposes, including
research, consumer satisfaction, proﬁt and clinical experience, whereby
it has been unclear which aims, or combinations of these aims, have
been prioritised.
Using the example of Beike Biotech (People's Republic of China
[PRC]), I will illustrate how a broader notion of ethics based on the abil-
ity to internalise and externalise (in/externalise) local factors can im-
prove our understanding of the bionetworking that underlies clinical
stem cell interventions.
1.3. Method and aim
‘Western’ discourses on the acceptability of clinical stem cell inter-
ventions often focus on the themes of payment, ethics and scientiﬁc ev-
idence. Thus, asking patients for payment for clinical stem cell services
and products that are not recognised by the international stem cell re-
search community, stem cell intervention without independent re-
search and ethical oversight, and providing stem cell interventions
unsupported by scientiﬁc evidence, are regarded as unethical
(Kiatpongsan and Sipp, 2009; Lindvall and Hyun, 2009; Gunter et al.,
2010). To examine the application and relevance of these criteria (pay-
ment, ethics and scientiﬁc evidence) in China, in July 2012, November
2012, and March 2013, I asked 43 medical professionals, life scientists
(20), medical doctors (14) and ethicists (9) for their views on the ac-
ceptability of the stem cell therapy provision services by Beike Biotech,
a companywidely criticised for charging exorbitant prices for unproven
stem cell therapies. When told that in the eyes of foreigners Beike Bio-
tech engages in unethical practices, the 18 interviewees that had not
lived abroad showed surprise. Only those that work in both China and
the US or had been abroad for over a year found Beike ‘unethical’, for
reasons of charging high fees, for using unproven and unauthorised
therapies, and for not having open patient records.
There is great variety in quality among stem cell research centres
and therapy providers in China, and it is not easy to gaugewhether ther-
apies are evidence-based, whether patient fees cover costs or constitute
proﬁt, and whether a lack of research oversight means that unaccept-
able research is taking place. Nevertheless, reports exist about clinics
that provide injections of cells of unclear provenance for steep fees
and without scientiﬁc records for diseases widely believed to be incur-
able. These so-called ‘rogue’ clinics are usually contrasted with clinics
that, as part of large-scale registered clinical trials, provide injections
of precisely documented cells in a clinical study without charging fees.
Using the notion of bionetworking, which presumes a connection be-
tween the production of scientiﬁc knowledge regarding life and a
moral economy that involves weighing political, economic and cultural
values, this article shows that most treatments can be found in an ethi-
cally grey area of stem cell experimentation combining research and
treatment in various forms. To do this, ﬁrst, I have analysed interview
materials collected from 2012 to 2013, and, second, using the theoreti-
cal notions of in/externalisation, I have analysed the ‘grey area’ of the
entrepreneurial aspects of stem cell interventions under different con-
ditions and in different settings.
The interviews were analysed by repeated readings, thematic con-
tent analysis, and the identiﬁcation of signiﬁcant examples, using the
abductive method (Timmermans and Tavory, 2012). By analysing the
Table 3
A hypothetical research ethics continuum.
The binary between Random Countrol Trials and Stem Cell Experimentation
Snake oil Stem cell experimentation
against payment
Compassionate
treatment
Hospital exemption
(EMA)
Conditional marketing approval before evidence
(post-marketing data collection requirement)
Randomised clinical trial
(Phase I–IV)
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provided by Beike Biotech, I argue that most stem cell interventions
take place in a large grey area, in which narrow notions of ethics
(i.e., treatment provided is based on scientiﬁc evidence, experimental
treatment requires nopayment, any treatment is provided under ethical
oversight) are blurredwith and supplanted by broader notions of ethics,
co-determined by estimations of socio-economic, political and cultural
understandings of risk and beneﬁt. By probing into the externalisation
and internalisation of local factors inﬂuencing both stem cell research
and therapeutic products, I aim to introduce a newdimension to the ap-
praisal of the ‘ethicality of research’. In doing this, I intend to broaden
the basis for understanding what is viewed as acceptable stem cell
therapy.
After a brief discussion of different forms of stem cell experimenta-
tion, I will introduce in detail the in/externalisation of local factors in
clinical stem cell interventions, before introducing the case of Beike Bio-
tech. The case study is followed by a discussion of the applied method
and its shortcomings and a conclusion. The research has received ethical
certiﬁcation from the ethical review board at the University of Sussex.
2. Distinguishing between forms of stem cell experimentation
Awareness of clinical stem cell applications as bionetworks focuses
our attention on the entrepreneurial aspects of research ﬁnance
(e.g., research funding, science investment, treatment fees), research
policies (e.g., regarding standards, expertise, regulation, research data)
and life values (e.g., values pertaining to health, bioethics, distributive
justice) involved in life science innovation.
Experimental research that strictly follows scientiﬁc protocol, such as
the four-phased, double-blind, randomised control trial with control
groups, is designed to meet the standards of the world's leading peer-
reviewed international scientiﬁc journals. The general validity of the
RCT would make these trials universally repeatable and applicable.
These kinds of trials are extremely expensive, not in the least because
they need tomeet the highest standards of GMP, GLP and IRBs, to be con-
ducted by trained personnel, and have supervisory mechanisms in place
towork according to authorised scientiﬁc protocol. SuchRCTs are thought
to be ‘scientiﬁc evidence-based’ and, ultimately, most beneﬁcial to pa-
tients. However, wherever the intervention takes place, in practice
many of the formal rules for clinical application and the ‘patients’ derive
from high-income countries (Hunt and Khosla, 2010; Nwobike, 2006).
The research ethics of translational stem cell research and stem cell
therapies are difﬁcult to delineate in a consistent manner. I started out
to explore this question using a ‘research ethics continuum’ ranging
from ‘rogue’ to ‘bona ﬁde’ stem cell applications, with RCTs as one ex-
treme and ‘snake oil’ applications as the other Table 3:
Although helpful in the European context, such a continuumcan also
bemisleading. For,whatwe call ‘rogue’ practices can become acceptable
depending on the context in which they occur. In the case of patients
with severe, intractable diseases, ‘patient-driven experimentation’ is
performed in hospitals around the world. In cases where innovative
cell products involve the testing of new procedures or drugs, regulatory
provisions can be made. For example, doctors in Europe can nowmake
use of the ‘hospital exemption’ (EMA, European Medicines Agency,
2010), while doctors in the US can test new treatments using the ‘com-
passionate use programmes’ (Moynihan, 2012). But all of these clinical
stem cell interventions are required to follow scientiﬁc protocol, inde-
pendent review by an Institutional Review Board (IRB), and ethicsprocedures. In the case of the hospital exemption in Europe, experimen-
tal treatment forms part of the research framework in the form of a
‘pilot-study’. Although these studies aim to systematically collect data,
they are required to prioritise the welfare of the patient. In some coun-
tries, such as Spain, the number of patients involved can amount to hun-
dreds of patients, while others only allow 10 (interview F, Leiden, April
2012). These forms of experimental treatment require doctors to weigh
the beneﬁts/costs of the new treatment against those of all other treat-
ments available to the patient.
Another form of experimentation takes place in the context of what
is often referred to as ‘stem cell tourism’ (Song, 2010), where clinics
provide stem cell therapies for a wide range of serious diseases for
high fees (Lindvall and Hyun, 2009; McMahon and Thorsteinsdóttir,
2010). Especially where there is little regulatory oversight of ‘scientiﬁc’
stem cell research practices, therapies may be applied with or without
quality control and at all stages of the disease. Routine use of treatment
proceduresmakes the practitioners of this form of proﬁt-driven therapy
highly experienced in the handling and the banking of cells, and the
treatment procedures employed. Providers can use this work experi-
ence to claim expertise in clinical stem cell procedures, including
those that are not accepted by the prestigious scientiﬁc journals. As ex-
empliﬁed in the case study of Beike Biotech, discussed below, such pro-
viders have begun to set up databases (planned or post-hoc) and gather
material to examine the safety and efﬁcacy of the therapies.
Ethical research is important for the safety of patients and the protec-
tion of the reputation of scientists. But the ethicality of stem cell experi-
mentation is difﬁcult to gauge in universal terms of treatment fees,
ethical oversight, and scientiﬁc evidence used in the literature (Lindvall
and Hyun, 2009; Gunter et al., 2010). This is because practices such as ﬁ-
nancial payment for medical interventions, using ‘experimental therapy’
as regular therapy, and the acknowledgement of possible patient beneﬁt
from experimental research are accepted in large parts of the world.
First, ﬁnancial contribution to treatment is a conventional practice,
also used in countries providingﬁrst-class healthcare. Thus, pilot studies
for experimental treatment usually do not charge fees, but can ask for a
contribution to the direct cost of the therapy (e.g., hospital bed, medi-
cine and nursing) and insurance. For instance, in Japan patients pay
for the basic costs of new drugs that have not passed the PMDA yet,
and in the USA, the Code of Federal Regulations (CFR) 312.8 allows
charging for investigational drugs under IND (USA GPO, 2012).
Second, in many countries clinical trials, which are also experimental,
are regarded as a realistic healthcare opportunity, despite the lack of evi-
dence of the efﬁcacy ofmedical interventions. Thus, in countries with low
standards of healthcare provisionpatientsmayview foreign experimental
medicine as their best option, evenwhen risks are involved that are unac-
ceptable elsewhere, and even if medicines are not guaranteed after the
trial.
Third, clinical trialsmay have adverse effects that require family care
when the RCT does not take responsibility. Thus, some RCTs address na-
tional insurance schemes ﬁrst in case of adverse effect, or fall back to
care by family members when no hospital care is available (personal
communication, IRB member in a hospital in Suzhou, China).
Finally, some providers of stem cell interventions are more seriously
interested in research results than therapy outcome, while others are
not interested in either. Awareness of this ‘risk hierarchy’makes scien-
tists more tolerant of some than other forms of ‘rogue’ therapy provi-
sion. Thus setting up GLP/GMP clinical trials of considerable risk
without government permission may be regarded as less harmful
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tions (interview P, R, D March 2013; M, B, K July 2012).
These observations show that local circumstances and diverging
healthcare contexts put into perspective the ethics criteria associated
with idealised RCTs. There are also other, more general, reasons why
the ethical appraisal of stem cell interventions cannot be deﬁned in uni-
versal ethical terms.
First, scientiﬁc appraisal can be problematic, due to dissent among ex-
perts and their competing interests (Bianco, 2013; Centre for
Bionetworking, 2014). When investigating plans for clinical studies,
most governments ﬁnd it hard to know which camps of scientists are
the ‘most scientiﬁc’ or reliable. Among scientists in China there are
those who support relaxed guidelines for translational medicine and
others who insist on strict legislation. This situation is complicated by
the systematic pressure exerted by sceptical expertswho lobby for invest-
ment into public health or epidemiology (interview public health expert
S, July 2012, Shanghai).
Second, patients want cures, independent of whether they are
achieved through scientiﬁc knowledge, ﬂuke, placebo or alternative
treatments. To patients that cannot afford or ﬁnd alternative
healthcare in their country, commercial or experimental stem cell
therapies may be their only option – especially if they see this as a
chance for a higher quality or extension of life. A growing group of
patients argues that any positive effect, even if the result of a place-
bo, and even if short-term, is preferable to no intervention (Chen
and Gottweis, 2013).
Third, many patients do not think that paid-for treatment is auto-
matically unethical. Although making proﬁt using experimental medi-
cine is unethical according to some, many patients understand that
those providing commercial stem cell interventions do not necessarily
regard patients as amere source of proﬁt. Rather, they need tomaintain
the viability of their enterprise to help patients (personal communica-
tion spinal cord injury patient, Nov. 2013).
Fourth, both patients and scientists acknowledge that experi-
ments are needed for the advancement of science, but different loca-
tions organise these in different ways. Thus, the hospital exemption
in the EU and compassionate treatment in other countries are mech-
anisms that allow trying out innovative treatments on a limited
number of patients. Many researchers regard small-scale studies as
expedient to yielding data of, for instance, innovative stem cell-
based treatment for a complex and multi-systemic condition such
as Parkinson's Disease as preparation of large-scale clinical trials
(Hyun, 2010). Such experimental spaces are also claimed in China
(interview P, March 2013).
Although conditions of poor healthcare access lead patients to opt
for risky treatment, it is also true that patients fromHICs andwealthy
people in LMICs without conventional treatment options ﬂock to the
same stem cell therapy providers. In addition, there are patients that
have invested their life savings (andmore) into the desired interven-
tion. The patients go on a ‘stem cell pilgrimage’ (Song, 2010) despite
warnings given by doctors and placed on the websites of the Interna-
tional Society for Stem Cell Research (ISSCR, 2008) and the Interna-
tional Society for Cell Therapy (ISCT, 2015) guidelines. It is clear,
then, that understanding the provision of stem cell interventions
requires an approach that analyses the reasons for provision and de-
mand together.
To appreciate the workings of the bionetworks in which stem cell
experimentation operates, rather than judging it by a narrow ap-
proach to bioethics, commercial aims, and research oversight alone,
it is important to understand the healthcare needs of patients and
the infrastructural resources available to populations. Ethics over-
sight, fee-payment and scientiﬁc evidence are only some of the
aspects relevant to the exchanges between patients, doctors and
life scientists, which are better understood in the light of the globalisa-
tion of the healthcare industry in interaction with the ways in which
localities aim to meet local needs.3. The internalisation and externalisation of local factors
The binary of RCTs and SCE blinds us to the bionetworks that com-
bine elements of both in clinical applications. The clinical interventions
of RCTs would follow ‘scientiﬁc’ protocol to improve the state-of-the-
art, and ultimately to create medical products that can save people's
lives. The ethicality of RCTs has however been queried, as research in
LMICs requires making adjustments to ﬁeld sites through the exter-
nalisation of local factors that inﬂuence the protocol of a clinical
trial (Will, 2007; Geissler et al., 2008: 705; Rothwell, 2005). Thus, a
multi-centred, randomised stem cell trial for a certain non-
communicable disease in a developing country needs to take into ac-
count characteristics of the patient populations and the research in-
frastructure. The other extreme of the binary, SCE, would exploit
desperate populations by charging high payments for unproven
stem cell interventions, making use of the vulnerabilities and fea-
tures of the incurable, such as their desperation, naivety, lack of
healthcare access, and wealth. In terms of the internalisation of
local factors, these features could translate into the business pros-
pects of ‘rogue’ stem cell interventions.
But a closer look at the internalisation and externalisation of local
factors sheds light on the signiﬁcance of ‘ethical oversight’, ‘fee pay-
ment’ and ‘scientiﬁc evidence’ in therapy provision, and yields insight
into the process of the value realisation of clinical stem cell interven-
tions as bionetworks. The life scientists interviewed were asked about
the kinds of populations important for recruitment to test clinical
stem cell applications in terms of the ‘features of patient populations’
and the ‘biomedical infrastructure’ needed (summarised in Table 4).
The reasons for and the priority of their interest in the features of a par-
ticular patient population and the available research infrastructure var-
ied greatly, and were dependent on interviewees' emphasis on the
importance of research, therapy, or both, and on their views on the
availability of resources. Below I explain this in terms of the in/external-
isation of local factors.
3.1. Externalisation
To realise optimal research conditions, interviewed life scientists
had various priorities: a location with advantageous regulation, a suit-
able patient disease pool, skilled collaborative partners of good reputa-
tion, certiﬁed scientiﬁc institutions, and the public acceptability of the
research. Various intervieweesmentioned that, in some infrastructures,
the research participants might require pre-treatment, simulating the
standardised health conditions of ‘ﬁrst world countries’, in preparation
for the trial: after all, ﬁnal products will need to reach high-demand
markets. Thus, to optimise standard treatment, the participants would
need to be precisely instructed (language; education) about the sanitary
conditions (hygiene; diet), duration of the treatment (family circum-
stances), and its costs (insurance; transport; time off work or away
from home).
There was awareness among most interviewees that, if and when
medical products result, they might not beneﬁt the tested population,
as after the trial the population is expected to revert to its pre-trial life-
style. Thus, even if the cost of the medical intervention would be met,
the tested population may require sanitary conditions, hygiene, nutri-
tion, knowledge, time and transportation normally not available in
their everyday lives. The concern about being in the right condition to
receive treatment is not just associated with RCTs, but with all modes
of clinical research that require human research subjects to adopt sub-
stantial lifestyle changes, whether RCT, small-scale investigative stud-
ies, compassionate interventions, or pay-for-treatment studies (which,
in addition, involve large payments, new medical regimes, suitable liv-
ing environments and employment, and follow-up treatment). The
availability of continued treatment or treatment for members of the
tested population, interviewees pointed out, cannot be taken for
granted even if ﬁnancial support is available.
Table 4
The local factorsmentioned by life scientists as being important to patient recruitment for
clinical research (in order of frequency mentioned):
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for creating medical products that are unaffordable due to intellectual
property rights (iPR). However, medical products generated outside of
RCTs can also carry iPR. For instance, Beike Biotech, who does not orga-
nise classical RCTs, promotes its 20 patents and AABB certiﬁcate (Beike,
2014a) in advertisements and in its negotiations with provincial
biobanks and hospitals. And, Beike's stem cell products can be just as
unaffordable, as will be illustrated below.3.2. Internalisation
The scientiﬁc basis of the researchmay be affected by the social and
physical circumstances in which it takes place, for it is not always possi-
ble to externalise the ‘undesirable’ conditions that are part and parcel of
the ﬁeld site (Montgomery, 2012). In such cases, they are unavoidably
internalised into the research. This was clearly recognised by the inter-
viewees engaged in clinical trials (P March 2013; H, O Nov. 2012), who
indicated that research participants bring into the research their partic-
ular social conditions related to healthcare, diet, medicine, physiological
idiosyncrasies, hygiene, and attitudes that shape the reaction of the ex-
perimental body, and which may inﬂuence the results of experimental
research. In other words, the undesired internalisation of local condi-
tions may be unpreventable, and introduce bias into the research, as is
the case with pragmatic clinical trials (Patsopoulos, 2011; Sugarman
and Califf, 2014).
Some local factors, including healthcare access, regulatory re-
gimes, and the socio-cultural background of various populations,
are ambiguous, as they can seem to be external to clinical stem cell
interventions. They are nevertheless internalised for various rea-
sons. For instance, the socio-cultural background or ‘ethnicity’ of a
population can be pertinent to the ‘scientiﬁc logic’ of clinical re-
search when the population is thought to be sensitive to certain
chemical components in drugs. In other cases, ethnic background
can be expedient to lucrative clinical stem cell research ventures
when internalised strategically. Thus, if a group of patients with a
certain social or ethnic background is known to lack healthcare ac-
cess (cf Medpace, 2013), it may become the target of patient recruit-
ment (interview, Q July 2012). In such cases the internalisation of
ethnicity serves proﬁt-making.Some interviewees criticised ‘irresponsible’ clinical stem cell inter-
ventions as ‘experimentation’ for ignoring the particularity of disease
conditions, such as when the same stem cell intervention is applied
for both Parkinson's and Huntington's Disease (N, Z Tianjin, Nov.
2012). In this case, the variability of patients' conditions remains ‘un-
marked’. However, the failure tomark the particularity of a potential pa-
tient population also occurs in RCTs, such as when the size, ethnicity,
weight, age and other physiological features of patients are not taken
into account (Leichleiter, 2014). Participants in RCTsmay also be select-
ed for their particular characteristics, be it geneticmake-up, medical na-
ivety, lack of alternative treatment, or absence of strict regulation in the
country the RCT takes place (Sleeboom, 2005; Pomfret and Nelson,
2000; Petryna, 2007, 2009). Even though in such cases patients may
not have to pay for participation, they take a considerable medical risk
and have no guarantee that any potentialmedical products will become
available to them.
The reasons for the internalisation and externalisation of features
of the targeted patient population and its environment vary, and are
inherent to the bionetworks they are part of. Aspects of experimental
conditions are internalised not just because they are hoped to con-
tribute to the state-of-the-art or to beneﬁt patients, but also because
other interests play a role, such as reputation, market-share, proﬁt,
or contact networks. Similarly, knowledge of the patient's healthcare
access, insurance, education, religious belief, wealth, living condi-
tions and family situation may all be valuable for patient recruitment
purposes, while knowledge of a country's healthcare system, regula-
tion, patient pool, communication system, expertise, jurisprudence,
insurance system and science policy are important to the location
of stem cell clinics. Interviews made clear that such knowledge of
localised conditions underpin the organisation of clinical stem cell
application in general, including in the work of clinical research
organisations (CROs), state hospitals and commercial stem cell
applications.
4. Why Beike Biotech is ‘acceptable’
By interpreting Beike Biotechnology as a bionetwork that internal-
ises and externalises local factors, I explainwhymany Chinese life scien-
tists refer to Beike Biotech, which is often referred to as ‘unethical’, as an
‘acceptable’ provider of stem cell interventions. This case shows how
Beike's bionetworking activities enabled it to gradually evolve from
being able to in/externalise only a few factors to being able to selectively
pickwhich factors to in/externalise. Before ethically adjudicating the ac-
tivities of clinical stem cell providers, understanding the stem cell inter-
ventions as part of bionetworks can help us to explain more
constructively why unauthorised stem cell interventions are used in
some locations but not in others.
Beike Biotechnology was set up in July 2005 in Shenzhen by Xiang
Hu (SeanHu), and the company specialises in stem cell research, clinical
translation, and technology support services of adult stem cells. Since
2005, Beike has provided stem cells for clinical application to over
16,000 patients suffering from neurological, hepatic, vascular and
other conditions (Beike, 2014a). After receiving his PhD from Columbia
University in 2001, Xiang Hu returned to Zhengzhou University, his
almamater in China, where he focused on translational research for se-
verely disabled patients. After he attracted capital from Hong Kong Sci-
ence & Technology and Qinghua Universities, Hu decided to set up his
company in Shenzhen in the South of China. In 2006, the Shenzhen gov-
ernment invested 900 k RMB (US$4m) into its industrial zone, to which
it invited Beike to set up its headquarters, and, in 2009, Beike opened its
Stem Cell Regenerative Medicine Industrial Complex in Taizhou, calling
it “the world's largest stem cell storage and processing facility” (Beike,
2009). Beike set itself an international mission:
Beike is the world's largest stem cell provider focusing on the re-
search, product development, and clinical translation of adult stem
cells as well as immunotherapy. Our goal is to increase communication
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Before 2009, in China no ofﬁcial permissionswere needed for clinical
stem cell research and no rules guided the application of experimental
stem cell therapies (Sui and Sleeboom-Faulkner, 2015). Until 2009, ap-
proximately one hundred stem cell companies and 400 hospitals had
applied stem cell transplantation for clinical therapy against high treat-
ment fees (Cyranoski, 2012). But in 2009 theMinistry of Health enacted
theManagementMeasures for the Clinical Use of Medical Technologies,
requiring permission for stem cell clinical application. Stem cells appli-
cations were ranked as ‘category three’ medical technology, entailing
the possibility of serious ethical problems, and safety and efﬁcacy issues
in need of being proven by clinical trial, though the rules did not carry
punitive measures. Although themedia referred to the inadequate gov-
ernance of clinical stem cell research situation sporadically as ‘stem cell
chaos’, and various sets of regulation were introduced (Sui and
Sleeboom-Faulkner, 2015), Beike Biotech continued to grow.
Nevertheless, it has been heavily criticised internationally. One critic
said of Beike:
Beike is one of the biggest and baddest of all the companies that have
made their millions selling untested, unregulated and uncontrolled
stem cell injections to patients suffering from a wide range of serious
diseases (Sipp, 2011).
Butwithin China, Beike has also receivedmuch sympathy, if not sup-
port. Here I make use of interviews with life scientists and regulators to
show why Chinese medical professionals and ethicists express confu-
sion and surprise at hearing about the dominant image of Beike Biotech
outside China as ‘unethical’.
Beike itself organises international patient recruitment through
agencies for stem cell tourism, and through websites, on which it col-
lects information about the medical records of patients, their ability to
pay, their insurance coverage, and their family situation (interviews
2012–3). Most of the providing hospitals are private, and are endowed
with various levels of luxury and treatment methods to cater for pa-
tients of different means and taste (hospital visits in Beijing, Shanghai,
Tianjin, Guangzhou, 2012–3). Staff at Beike Biotech said that they regard
the fees for the stem interventions as ‘similar to buying a car’ (Interview
D, March 2013, Shenzhen), but for many patients the 30-100 k RMB
means a fortune. Beike employees justify prices in reference to the li-
cencing fees that ‘American’ corporations levy from laboratories in
China (ibid). At the same time, some Beike employees are dissatisﬁed
that proﬁts are invested into luxury items rather than into facilities for
conducting research (Interview D, March 2013). Although Beike did
not have Chinese Food & Drugs Administration (CFDA) permission to
provide stem cell therapy, it continued conducting medical trials and
providing stem cell interventions at least until my visit in 2013 (see,
http://clinicaltrials.gov)1 through collaboration with a range of hospi-
tals, universities and local governments. The medical trials were partly
ﬁnanced by provincial governments and cities, and took place in private
and military hospitals. Most are run in (high-ranking) third-tier hospi-
tals by medical doctors (interview R, Guangzhou, March 2013), which
are keen on increasing the number of private patients.
Although, as mentioned, articles critical of stem cell tourism have
appeared in the Chinese media (Lue, 2013), Beike's scientiﬁc image is
not usually disputed. Interview responses indicate that it is mainly the
scientists that have part-time jobs abroad or have resided abroad for a
prolonged period of time (over a year)who are aware of the poor scien-
tiﬁc reputation Beike has outside China: not keepingmedical records for
outsiders to inspect, providing unproven therapies to patients, and tak-
ing advantage of the placebo effect, not publishing its results in interna-
tional science journals of reputation (e.g., Lim, 2008;McCullough, 2008;
Johnson, 2010; Tam, 2011; Brown, 2012; Chen and Gottweis, 2013).1 http://clinicaltrials.gov/ct2/results?term=beike&Search=Search (this search has
been conducted on June 25, 2013). [Last accessed: July 2, 2013].The life scientists that ﬁnd Beike's enterprise acceptable treat such
views as false allegations by referring to Beike Biotech's website, articles
and company events. This is a summary of their defence of Beike as
acceptable:
(1) Over the last years Beike has built up a rich experience of therapy
provision, simultaneously engaging in collaborative research and
clinical trial, which has led to the joint publication of articles in
international journals such as Journal of Translational Medicine,
PlosOne and Stem Cells (also see, Beike, 2013a).
(2) In 2009 Beike was visited by President Hu Jintao and Premier
Wen Jiabao, who praised Beike's scientiﬁc and therapeutic com-
petence in comparison with the world's most renowned life sci-
ence hubs (Anon, 2010).
(3) As for the placebo effect, interviewees argued that if it is true that
the scientiﬁc basis of stem cell therapies is not clearly understood
yet, then it is also unclear whether or not any signs of improve-
ment are attributable to any placebo effect (interview H, J, K 1,
July 2012).
(4) Although patient records have not been maintained in the past,
Interviewee L said that they are being kept now, but cannot be
opened for inspection by competitors and audit for reasons of
iPR and patient conﬁdentiality (interview M, July 2012). Those
who want to know more were referred to Beike's website,
which has patient case studies for the world to admire (Beike,
2012a).
(5) Any queries about the provenance of the stem cells used in ther-
apy are referred to the umbilical cord blood (UCB) banks Beike
runs and its connection networks (Beike, 2012b). Collaboration
with provincial governments in the management of provincial
UCB banks and the state support it receives through grants and
collaborations (Beike, 2013b) were cited in indicating Beike's re-
liability.
(6) Interviewees referred to the world's ‘highest certiﬁcate for blood
banking’ (AABB) Beike received in 2012 (Beike, 2012c).
It is clear that over the last 10 years Beike has undergone substantial
changes. Its capacity to in/externalise factors has increased. Beike has
moved from a situation in which it did not have sufﬁcient capacity to
make distinctions between the various conditions of patients, use clini-
cal methods, write publications in internationally peer-reviewed
journals, and provide rehabilitation, and it had little experience with
the banking of stem cells and tissues and keeping patient records. Fail-
ing to mark patient conditions, methods and materials, Beike could
not sufﬁciently externalise local factors tomake its research ‘universally
valid and repeatable’ through, for example, keeping patient records,
testing drug regimes, training patients to observe medical regimes,
and testing rehabilitation methods. Neither was it clear whether Beike
internalised patient conditions to address research questions relevant
to the particular patient populations it was targeting through pragmatic
trials. It was only seen to internalise factors for lucrative purposes: pa-
tients' ﬁnancial background, their lack of alternative treatment options,
and their hope.
The fact that patients had to pay for ‘experimental’ interventions,
most of the life scientists I interviewed in 2012 and 2013 did not regard
as unethical per se. After all, therapies falling outside China's local
healthcare provision lists were largely sold on a commercial basis, and
total healthcare insurance coveragewas rare. Patientswere used to pay-
ing for private and authorised therapies. Furthermore, the practice of
giving ‘red envelopes’ (bribes) to create goodwill is common (Yang,
2007); and, while patient choice of medical doctors/surgeons has be-
come a right in China, many patients nevertheless pay extra. The obser-
vation that Beike's services attract ‘foreign’ patients, who until recently
paid twice the amount Chinese patients did (interview D March 2013,
Shenzhen), was regarded as further proof in support of the reliability
of Beike's services. Considering that there were no other affordable
healthcare options for most patients, and that established life science
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applications (Xinhua, 2013), Beike, according to interviewees, was an
obvious alternative, also for patients that do not suffer from life-
threatening or intractable conditions.
Gradually, Beike's ﬁnancial and research capacity has become a sub-
stantial force in China's regenerative medicine industry. A brief descrip-
tion of the evolution of one of Beike's stem cell collaborations with
Drum Tower Hospital and Jiangsu University in Jiangsu, an important
link in its stem cell network regarding the study of systemic lupus ery-
thematosus (SLE), illustrates this. The bionetwork, which has evolved
since 2010, shows how Beike's capacity to select its in/externalisation
has increased dramatically (Beike, 2010). After years of experience
with stemcell applications, the collaborative network formulated a clin-
ical trial, whichwasﬁnanced by JiangsuProvince (US$1.8million) to de-
velop clinical applications usingmesenchymal stem cells fromumbilical
cord blood to treat SLE. A division of labour emerged, whereby Beike
provided the facilities, equipment, management framework, and pro-
prietary clinical stem cell technologies for the project, and Nanjing Uni-
versity Medical School's Drum Tower Hospital, experienced with
clinical studies of SLE, took care of administering the human trials and
enlisting of 200 patients, while Jiangsu University brought its biological
research and development resources to the production and animal
study phases to the project (Sun et al., 2010). In 2014, the group pub-
lished their study results in, among others, one of Biomed Central's ﬂag-
ship journals Arthritis Research & Therapy (cf Wang et al., 2014). It had
recruited forty patients with SLE from four clinical centres in China
and infused them intravenously with allogeneic UC MSCs at speciﬁc
times, ﬁrstly, to test safety proﬁles, and secondly, to test clinical re-
sponse. Clinical indices, including Systemic Lupus Erythematosus Dis-
ease Activity Index (SLEDAI) score, British Isles Lupus Assessment
Group (BILAG) score and renal functional indices, were also taken into
account. The article shows attention to safety, clinical response and re-
lapse to an extent that Beike would hardly have been capable of before
2009. But due to a focus on narrow deﬁnitions of bioethics, these chang-
es occurred unobserved. While in 2012 Beike's President Xiang (Sean)
Hu was still criticised for being a Stem Cell Madman in Entrepreneur
(see Note 2), in October 2013 Beike submitted the Investigational New
Drug (IND) application to register their UC MSCs for clinical use to the
Guangdong Province FDA and was accepted. In March 2014, the CFDA
ofﬁcially accepted the IND for review for clinical use (MarketWatch
2014).
This case-study of Beike Biotech shows why it is important to know
how and why local factors are in/externalised into the clinical research.
It allows us to discern the logic of ‘acceptability’ in its local context, such
as
• Whether patients pay fees to maintain the work of doctors and re-
searchers and exorbitant proﬁts that disappear into the pockets of in-
dividuals;
• Whether patients are told fairy-tales or whether they are given realis-
tic data on the therapeutic prospects;
• Whether interventions are uncontrolled try-outs or whether they are
part of larger-scale research;
• The source of certiﬁcations and the quality of publications (e.g.,whether
a company has its own journal or publishes in widely-known journals;
whether life scientists are main authors or free-riders on articles;
whether certiﬁcations are bestowed by suppliers or well-known insti-
tutions with authority).
The relation between local context and the bionetwork changes over
time: the chance of its conﬁguration can help us understand the drivers
of clinical research applications and whether they ﬁt the purported
purpose.
Viewing Beike as an entrepreneurial bionetwork enabled the obser-
vation of a broad range of activities around the provision of stem cellintervention and the development of stem cell products. Beike started
out using identical stem cells formany different conditions using similar
methods: it internalisedpatient demand, including the various payment
abilities and origin of patients by catering for their circumstances, and it
internalised a large range of diseases by applying methods and proce-
dures indiscriminately. Gradually, however, it built up experience, ar-
chives, and scientiﬁc capacity that improved its ability to subordinate
its internalisation efforts to a systematic approach requiring externalisa-
tion. Standardisation of patient records and intervention outcomes
made possible the diversiﬁcation of scientiﬁc protocol, while learning
enough about treatment effects to knowwhen not to treat led to the ex-
clusion of untreatable patients and the establishment of standard treat-
ment regimes of rehabilitation. Beike's efforts were made possible
ﬁnancially through the fees of patients and funding application efforts
by scientists, which led to lucrative collaborative arrangements with
hospitals, universities and governments, as a result of which Beike has
become amajor player in umbilical cord banking, has experience exper-
tise on stem cell processing, and has accumulated relationswith univer-
sities and hospitals that now posses extensive knowledge of stem cell
applications. Whether these constitute the world's state-of-the-art is
an important question from a scientiﬁc point of view, but perhaps not
most relevant to companies and institutes that wanted to improve
their start-position by catching up.
5. Discussion— the complexity of local factors and the grey area be-
tween RCTs and SCE
Observations of the in/externalisation of aspects of experimental
ﬁeld sites, including data on the patient population and their living con-
ditions, can help indicate whether experimentation contributes to re-
search efforts and the beneﬁt of patients. In the case study above, I
have argued that, if the internal logic of experimental clinical interven-
tions cannot be explained satisfactorily in terms of the in/externalisa-
tion of factors in the interest of the research and the patient
(population), there is a possibility that it serves controversial aims, in-
cluding the pursuit of proﬁt at the expense of patients. This method is
much broader than the narrow approaches to ethics used thus far, and
a step forward in an attempt to create transparency in the large grey
area between RCTs and SCE. To ﬁnd out whether taking into account
local factors is conducive to desirable stem cell interventions, we need
to know to what purpose local factors are mobilised, i.e., which aspects
of patients and infrastructures are relevant to the internal logic of an ex-
periment. Nevertheless, this method has its limitations.
First, the internalisation of patient characteristics such as environ-
ment, diet, genetic make-up, age, gender and weight can take place
for various reasons. For example, the logic of a clinical trial may require
information on body weight, ethnicity or gender to determine the most
appropriate drug dosage. But clinical trialsmight also include criteria for
age and body-weight with the aim of extending a patent, even though
the additional knowledge gained from the trial is of no scientiﬁc signif-
icance or relevance to the patients (Angell, 2004). In still other cases, the
criteria for diet, genetic make-up, age, gender and weight may be seen
as essential for the introduction of a therapy into a country, an argument
that Japan has used in negotiations with ICH (International Conference
on Harmonisation of Technical Requirements for Registration of Phar-
maceuticals for Human Use, Kuo, 2007). It is important, then, to know
whether the reasons for including epidemiological, social and cultural
criteria are political, ﬁnancial, medical, or research related.
Second, views on the effects of stem cell intervention usingMSCs are
contested. Some stem cell scientists accuse providers of failing to distin-
guish between disease proﬁles, such as Alzheimer Disease, diabetes,
Parkinson's Disease and Spinal Cord Injury (SCI). Some scientists regard
the safety and efﬁcacy of MSC therapies as unproven and therefore un-
ethical if commercially provided (Bianco, 2013; Bianco and Sipp, 2014;
Paterlini, 2014). Providers justify their interventions by referring to the
ability of MSCs to secrete paracrinal factors and cytokines that
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scientist who oversees a well-equipped lab in Shanghai (interview L,
Nov. 2012, Shanghai), it is by no means clear how many cells should
be administered and by what method, where the cells go, and whether
they home-in, transform or disappear. Other scientists, including some
at Beike (interviews DMarch 2013; Y, Nov. 2012), say that the interven-
tion has a short-lived effect (3–6 months at the most - interviewees
Shanghai, Shenzhen, Beijing and Guangzhou). Internationally, the num-
ber of clinical trials using MSCs registered on the website clinicaltrials.
gov, a US National Institute of Health database that provides patients,
family members and the public with information about current ongoing
clinical research studies, has increased, but the way MSCs work remains
disputed. Thus, the use ofMSCs in the treatment of Graft-versus-Host Dis-
ease (GvHD)was explained tomevariously as fusion, transdifferentiation,
and paracrine effect. In short, ‘the science’ is contested.
Third, there may be disagreement about the necessity of in/
externalising local factors, as scientists might disagree about whether
something is ‘particular’ and in need of externalisation. Thus, what are
regarded as unsuitable diet, unsanitary conditions and clashingmedical
regimes might be ‘externalised’ using ﬁnancial support, a ‘Western’
medical regime, nursing, antiseptic devices, and a pollution-free living
space during themedical trial. But to local patients these ‘particularities’
may be part of an unquestionable daily life. These ‘particular’ conditions
may need to be taken into account or be ‘internalised’ to the logic of the
research plan, so that any resultant medical products will suit their way
of living. Life-style factors (stress, housing, kinetic movement) and cul-
tural factors (gender- and age-speciﬁc traditions, fasting, religious rites,
conjugal habits) may have to be treated as ‘normal’ conditions for the
treatment to ‘work’ under locally ‘normal’ circumstances. As forMSC in-
terventions, rehabilitation therapy can be crucial to the efﬁcacy of the
intervention (Aoyama et al., 2015), requiring patients to maintain ‘nor-
mal’ daily activities. The question of whether environmental factors are
internal or external to the logic of treatmentmay be decisive to catering
for patient demands. Indeed, it is the question underpinning new re-
search trials in China initiated by Beike andmilitarymedical institutions
advertising their trials on clinicaltrials.gov.2 To complicate thematter of
‘acceptability’ of stem cell interventions, clinicaltrials.gov itself has be-
come suspect of legitimising irresponsible research (Piller, 2015;
Clarke et al., 2010: 72).Table 5
The strategic in/externalisation of local factors in medical trials to create biomedical
products.
Local factors Can be both in/externalised, e.g., healthcare, wealth, regulation,
culture, disorders, hygiene, ‘medically naïve’ population
Internalisation To adjust the research to the needs of a particular disease
population (beneﬁcial); to take advantage of the vulnerability of
patient groups (exploitative)
Externalisation To enhance the universal validity of research by adjusting the6. Conclusion
During the ﬁrst decade of thismillennium a disjunction between the
aims andmeans of biomedical interventions sharpened as a result of the
globalisation of personal networks of scientists returning to LMICs. Chi-
nese scientists that followed their education abroad, including Beike
Biotech founder Xiang Hu, were trained in ‘Western’ laboratories and
became well versed in scientiﬁc theory. When returning home, howev-
er, they landed in a very different institutional and regulatory environ-
ment, whereby the comparatively low standard of healthcare access
and scientiﬁc provisions made an orientation on patients unavoidable,
despite their research interests and activities. For over a decade now,
an increasing number of translational stem cell researchers, such as
those at Beike, have studied patient records post-hoc, and ventured to
test scientiﬁc hypotheses on the basis of knowledge garnered from sci-
ence journals and an increasing number of patient records. Thus, patient
observations in combination with deductive reasoning have served to
further knowledge in a pragmatic, experimental manner. Even what
some see as educated guesswork may lack systematic data collection,
the application of research/ethics regulation, and state-of-the-art equip-
ment and conditionsmay be directed at developing into something that
merits increasing ‘acceptability’.2 See http://clinicaltrials.gov/ct2/show/NCT01393977; http://clinicaltrials.gov/ct2/
show/NCT01929434).In this article, I argued that there exists a large grey area between
‘bona ﬁde’ RCTs and ‘rogue’ SCE, due to the narrow notion of ethics
used in writings about clinical stem cell research and interventions.
Rather than judging the acceptability of a stem cell intervention on
the basis of ethical review, fee payment and scientiﬁc evidence, this ar-
ticle views all institutions that provide stem cell interventions as part of
entrepreneurial bionetworks. The notion of bionetworking focused our
attention on the entrepreneurial aspects of research ﬁnance, research
policies, and life values involved in life science innovation. As illustrated
by the case study of Beike Biotech, bionetworking activities pertain to
the changing conﬁguration of the in/externalisation of local factors, in-
cluding features of disease populations and the environment, treatment
demand, healthcare provision, wealth, regulation and state-of-the art.
I invoked the case study of Beike Biotech to maintain that the use of
narrow ‘Western’ standards for stemcell science is unsuitable for appre-
ciating the variable conditions of stem cell science in LMICs, where
many researchers are side-lined due to a lack of resources. Critics regard
rebels such as Beike Biotech as unethical and greedy, as they use a com-
mercial agenda in the provision of stem cell products. In this context, I
made use of the notion of bionetworking to examine entrepreneurial
and strategic activities in life science research and clinical applications
to argue that life scientists, whether commercial or state supported, all
have entrepreneurial agendas, although they play out differently. In
summary, I showed that: if the entrepreneurial in/externalisation of
local factors by an enterprise (be it RCT, commercial provider or state in-
stitution) is unclear, hidden or exploitative, there is reason to be critical
of the clinical application Table 5.
I observed how local factors are internalised and externalised
through bionetworking activities. Externalisation excludes local features
and environmental factors of a population to enhance the universal va-
lidity of research application by adjusting the population or its environ-
ment; internalisation utilises local features and environmental factors of
a population in a research application to enable the application of re-
search products to particular populations. The externalisation of local
factors apart from in RCTs also occurs in other kinds of clinical research
application, such as in investigator-led clinical trials. The internalisation
of local factors, such as those of healthcare, wealth, regulation, culture
and hygiene, allows the application of a limited number of principles
to a diverse population. This can yield clinical interventions for particu-
lar disease populations in both exploitative and beneﬁcial ways. While
some research projects have started to internalise (utilise) local factors
to adjust the research to the needs of a particular disease population, the
internalisation of particular features of local populations, such as its
‘medical naivety’, disease conditions, and despair can take advantage
of the vulnerability of patient groups.
Examining how the in/externalisation of local factors underpin
Beike's development, I showed how ‘unethical’ forms of internalisation
have various functions, such as yielding proﬁt, clinical experience, re-
search results and patient data. These same functions have enabled
Beike to set up stem cell banks and scientiﬁc collaborations, conduct
and publish research, and engage in collaborative researchwith univer-
sities and hospitals. Although this does not mean that the company be-
haves in a way acceptable to the ‘international science community’, the
company does not just sell snake oil either. I have argued that, ratherpopulation (beneﬁcial to the ‘dominant’ population; exploitative,
if resulting medical products are not provided or suitable for the
participating population)
85M.E. Sleeboom-Faulkner / Technological Forecasting & Social Change 109 (2016) 76–86than just passing judgement, it is important to understand why and
how local factors are in/externalised into the clinical research: to beneﬁt
the research, the patients, or for other purposes. The conﬁguration of
the connection between local factors and the in/externalisation activi-
ties in a bionetwork over time can shed light on the local rationale be-
hind the acceptability of clinical research.
Rather than leading to a form of ethical relativism in the ﬁeld of re-
generative medicine, such improved understanding should alert initia-
tors of the creation of global research and ethical guidelines that they
will affect the clinical research activities of those who are excluded
from their formulation. ‘Snake-oil’ providers can be detected globally,
and are broadly condemned — there is no need for a formal ethical
framework against these, just a legal one. However, if ethics and re-
search guidelines are intended for global implementation, efforts are
needed to include in the regulatory process scientists from parts of the
world, whose practices may be frowned upon. This will require a
more realistic understanding of the ‘large grey area’ of clinical stem
cell research, and a reconsideration of the terms of global competition
in regenerative medicine, a ﬁeld widely perceived as fraught with ethi-
cally sensitive issues.References
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